LY2780301

LY2780301 is an orally bioavailable small molecule that acts as a dual inhibitor of Akt (protein kinase B) and p70S6K (70 kDa ribosomal protein S6 kinase). It functions as an ATP-competitive inhibitor, binding to and inhibiting the activity of both Akt and p70S6K. This inhibition disrupts the PI3K/Akt signaling pathway, leading to reduced cell proliferation and induction of apoptosis in tumor cells. The drug was developed primarily for oncology indications such as solid tumors, breast cancer, and non-Hodgkin's lymphoma. Its development was led by Eli Lilly and Company with contributions from Institut Paoli-Calmettes and Institute Gustave-Roussy[1][2][3][4][5][6].